Oral cannabidiol did not impair learning and memory in healthy adults
Open Access
- 23 January 2025
- journal article
- research article
- Published by Springer Nature in Journal of Cannabis Research
- Vol. 7 (1) , 1-11
Abstract
Background: The effect of oral Cannabidiol (CBD) on interference during learning and memory (L&M) in healthy human volunteers has not been studied. Method: A two-arm crossover, randomized, double-blind, placebo-controlled trial was conducted at Colorado State University Pueblo (CSU Pueblo) to evaluate the effects of 246 mg oral CBD on L&M in healthy adults. Among 57 healthy volunteers enrolled, 35 were included in the analyses. For assessment of L&M, Montreal Cognitive Assessment (MOCA) was used to evaluate verbal baseline cognitive function; RAVLT-R tests (List A and List B recalls, Proactive and Retroactive Interference ratios, and Forgetting Speed ratio) were used to evaluate verbal declarative memory; and total prose recall was used to evaluate verbal logical memory. Linear Mixed Models with Bonferroni Corrections were used to compare L&M results between primary outcomes (CBD vs. placebo) and secondary demographic outcomes, with a two-tailed statistical significance of P < 0.05. Results: CBD administration did not affect any of the dependent variables measured compared to the placebo group. There were no effects of THC, history of CBD use, or sex on CBD’s modulation of L&M. However, a highly significant interaction effect between treatment groups (CBD vs. placebo) and age of subjects was observed for the PI ratio (P = 0.008; n = 35). Conclusions: The results of this study suggest that administration of oral CBD alone does not significantly impair L&M in healthy adults. However, age might influence CBD related modulation of proactive interference during human L&M. Future research involving a larger group of older adults is needed to confirm this potential effect. Trial registration: The study was approved by the CSU Pueblo IRB, conducted in accordance with the Declaration of Helsinki, and registered with ClinicalTrials.gov (NCT06074172).Keywords
Funding Information
- Institute of Cannabis Research (Institute of Cannabis Research)
This publication has 70 references indexed in Scilit:
- Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical TrialJAMA Network Open, 2023
- Cannabidiol: pharmacology and therapeutic targetsPsychopharmacology, 2020
- The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trialPsychopharmacology, 2018
- Verbal learning and memory in adolescent cannabis users, alcohol users and non-usersPsychopharmacology, 2011
- Distinct Effects of Δ9-Tetrahydrocannabinol and Cannabidiol on Neural Activation During Emotional ProcessingArchives of General Psychiatry, 2009
- Cognitive and psychomotor effects in males after smoking a combination of tobacco and cannabis containing up to 69 mg delta-9-tetrahydrocannabinol (THC)Psychopharmacology, 2008
- Effects of Cannabinoids on Neurotransmission2005
- Cognitive and subjective dose-response effects of acute oral Δ 9 -tetrahydrocannabinol (THC) in infrequent cannabis usersPsychopharmacology, 2002
- Use of the california verbal learning test to detect proactive interference in the traumatically brain injuredJournal of Clinical Psychology, 2000
- Action of cannabidiol on the anxiety and other effects produced by ?9-THC in normal subjectsPsychopharmacology, 1982